Edition:
United States

People: OncoMed Pharmaceuticals Inc (OMED.OQ)

OMED.OQ on NASDAQ Stock Exchange Global Select Market

0.81USD
20 Feb 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$0.81
Open
$0.83
Day's High
$0.85
Day's Low
$0.80
Volume
166,695
Avg. Vol
82,394
52-wk High
$3.61
52-wk Low
$0.55

Hoey, Tim 

Mr. Timothy Hoey Ph.D. is Senior Vice President, Cancer Biology of the company. Previously served as our Vice President, Cancer Biology from 2005 to December 2009. Prior to that time, Dr. Hoey served as Director, Biology Department at Amgen (San Francisco), where he was responsible for characterization of oncogenes and development of drugs to target oncogene products. Dr. Hoey previously served as Director, Biology Department at Tularik Inc., a public biopharmaceutical company that was acquired by Amgen, Inc. in 2004. Dr. Hoey has authored or co-authored more than 60 published scientific papers and is listed as an inventor on several patents. Dr. Hoey received a B.S. in Biology from the University of Michigan and a Ph.D. in Biological Sciences from Columbia University.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --